



HIV Pathogenesis, Vaccine and Eradication Strategies

Guest Editor:

Dr. Mudit Tyagi

Thomas Jefferson University,
Philadelphia, USA

Deadline for manuscript
submissions:

closed (28 February 2022)

Message from the Guest Editor

Dear Colleagues,

Human Immunodeficiency Virus (HIV) is still a very big problem for humanity. Fortunately, current anti-HIV drug regimens are highly effective in controlling HIV transmission and replication. Notably, it has been well established that current anti-HIV therapy would not be able to eradicate or cure HIV. Numerous strategies have been applied unsuccessfully to flush out the latent HIV reservoirs, the main hurdle in HIV eradication. However, due to mutadaptability of HIV, both preventive and therapeutic vaccines have been proved ineffective. In addition, several other prophylactic approaches, including microbicides, are struggling to make impact.

We are interested in a broader area of research, focusing primarily on the mechanisms of HIV pathogenesis, life cycle, latency and therapeutics. In addition, we are calling manuscripts dealing with vaccine trials (pre-clinical and clinical) and strategies to develop more effective HIV vaccine. We are looking forward to have a combination of manuscripts that deals with different vital aspects of HIV, which could be exploited to develop more effective anti-HIV therapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com